高白细胞急性髓系白血病B细胞淋巴瘤因子2(BCL-2)的表达及临床意义

摘要

本研究旨在探讨B细胞淋巴瘤因子2(BCL-2)在高白细胞急性髓系白血病(AML)发病中的作用.采用流式细胞术(FCM)检测48例AML患者胞内BCL-2水平,采用酶联免疫实验(ELISA)检测40例AML患者血清BCL-2含量.结果表明:高白细胞和非高白细胞AML患者的血清BCL-2含量均明显高于正常人(P＜0.05),胞内BCL-2水平与正常人比较无显著性差异(P＞0.05).高白细胞、非高白细胞AML患者之间胞内及血清BCL-2含量均无显著性差异(P＞0.05).高白细胞、非高白细胞AML患者及正常对照者的胞内和血清BCL-2含量无显著相关性(P＞0.05).结论:AML患者的白血病细胞过多地产生BCL-2并分泌至血清,此结果可能参与AML的发生,但BCL-2的凋亡抑制作用对高白细胞AML的发病并未产生重要影响.%This study was aimed to investigate the role of B-cell lymphoma 2 (BCL-2) in pathogenesis of hyperleukocytic acute myeloid leukemia (AML).The levels of intracellular BCL-2 in 48 AML patients were detected by flow cytometry (FCM).Serum levels of BCL-2 in 40 AML patients were measured by enzyme-linked immunosorbent assay (ELISA).The results showed that the serum levels of BCL-2 in hyperleukocytic AML and non-hyperleukocytic AML patients were significantly higher than that in normal controls (P ＜ 0.05),but intracellular BCL-2 levels were not significantly different,as compared with normal controls (P ＞ 0.05).There were no difference of intracellular and serum BCL-2 levels between hyperleukocytic and non-hyperleukocytic AML patients (P ＞ 0.05).The serum and intracellular levels of BCL-2 between hyperleukocytic AML,non-hyperleukocytic AML patients and normal controls were not statistically correlated.It is concluded that leukemic cells in AML patients produce and secrete too much BCL-2,which may be involved in the pathogenesis of leukemia disease.However,the anti-apoptosis effect of BCL-2 has no significant impact on the pathogenesis of hyperleukocytic AML.